6533b85efe1ef96bd12c0892

RESEARCH PRODUCT

Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study.

Elizabeth A.m. FeijenWael Salem ZrafiIbrahim DialloLorna Zadravec ZaletelDaniela AlessiRahel KuonenThomas WiebeEva-maria HauJeanette Falck WintherEdit BardiMonica TerenzianiFrancesca BagnascoZsuzsanna JakabJulianne ByrneRodrigue M AllodjiMelanie KaiserLeontien C.m. KremerHilde ØFstaasHelena M. LingeMichael M. HawkinsThorgerdur GudmundsdottirLars HjorthMoncilo JankovicChloe J BrightFlorent De VathaireClaudia E. KuehniPäivi M. LähteenmäkiStine HøgsholtDavid L. WinterCarlotta SacerdotePeter KaatschReulen Raoul CJoyeeta GuhaMiranda M Fidler-benaoudiaStanislaw GarwiczGhazi DebicheGiao Vu-bezinDesiree GrabowRiccardo HauptCristina VeresNadia HaddyKwok WongAndrea BautzJop C TeepenDamien LlanasRoderick SkinnerFinn WesenbergFlora E. Van LeeuwenCécile M. Ronckers

subject

medicine.medical_specialtyColorectal cancerPopulation03 medical and health sciences0302 clinical medicineInternal medicineEpidemiology of cancerCOLORECTAL CANCER SCREENINGmedicineCumulative incidence030212 general & internal medicineGastrointestinal cancerFamily historyeducation610 Medicine & healthGASTROINTESTINAL CANCERCOLORECTAL CANCEReducation.field_of_studybusiness.industryIncidence (epidemiology)Gastroenterologymedicine.disease030220 oncology & carcinogenesisCohortCANCER EPIDEMIOLOGYbusiness360 Social problems & social services

description

BackgroundSurvivors of childhood cancer are at risk of subsequent primary neoplasms (SPNs), but the risk of developing specific digestive SPNs beyond age 40 years remains uncertain. We investigated risks of specific digestive SPNs within the largest available cohort worldwide.MethodsThe PanCareSurFup cohort includes 69 460 five-year survivors of childhood cancer from 12 countries in Europe. Risks of digestive SPNs were quantified using standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence.Results427 digestive SPNs (214 colorectal, 62 liver, 48 stomach, 44 pancreas, 59 other) were diagnosed in 413 survivors. Wilms tumour (WT) and Hodgkin lymphoma (HL) survivors were at greatest risk (SIR 12.1; 95% CI 9.6 to 15.1; SIR 7.3; 95% CI 5.9 to 9.0, respectively). The cumulative incidence increased the most steeply with increasing age for WT survivors, reaching 7.4% by age 55% and 9.6% by age 60 years (1.0% expected based on general population rates). Regarding colorectal SPNs, WT and HL survivors were at greatest risk; both seven times that expected. By age 55 years, 2.3% of both WT (95% CI 1.4 to 3.9) and HL (95% CI 1.6 to 3.2) survivors had developed a colorectal SPN—comparable to the risk among members of the general population with at least two first-degree relatives affected.ConclusionsColonoscopy surveillance before age 55 is recommended in many European countries for individuals with a family history of colorectal cancer, but not for WT and HL survivors despite a comparable risk profile. Clinically, serious consideration should be given to the implementation of colonoscopy surveillance while further evaluation of its benefits, harms and cost-effectiveness in WT and HL survivors is undertaken.

10.1136/gutjnl-2020-322237https://pubmed.ncbi.nlm.nih.gov/33139271